Literature DB >> 29481427

Neuraxial Anesthesia During Cesarean Delivery for Placenta Previa With Suspected Morbidly Adherent Placenta: A Retrospective Analysis.

John C Markley1, Michaela K Farber2, Nicola C Perlman3, Daniela A Carusi4.   

Abstract

BACKGROUND: General anesthesia (GA) is often selected for cesarean deliveries (CD) with placenta previa and suspected morbidly adherent placenta (MAP) due to increased risk of hemorrhage and hysterectomy. We reviewed maternal outcomes and risk factors for conversion to GA in a cohort of patients undergoing CD and hysterectomy under neuraxial anesthesia (NA).
METHODS: We performed a single-center, retrospective cohort study of parturients undergoing nonemergent CD for placenta previa with suspected MAP from 1997 to 2015. Patients were classified according to whether they received GA, NA, or intraoperative conversion from NA to GA. The primary outcome measure was postoperative acuity, defined as the need for intensive care unit admission, arterial embolization, reoperation, or ongoing transfusion with ≥3 units packed red blood cells. We additionally identified variables positively associated with intraoperative conversion from NA to GA during hysterectomy. Confounding was controlled with logistic regression models.
RESULTS: Of 129 patients undergoing nonemergent CD for placenta previa with suspected MAP, 122 (95%) received NA as the primary anesthetic. NA was selected in the majority of patients with a body mass index ≥40 kg/m (9 of 10, 90%), a history of ≥3 prior CDs (18 of 20, 90%), suspected placenta increta or percreta (29 of 35, 83%), and Mallampati classification ≥3 (19 of 21, 90%). Of 72 patients with NA at the time of delivery who required hysterectomy, 15 (21%) required conversion to GA intraoperatively. Converted patients had a higher rate of major packed red blood cell transfusion (60% vs 25%; P = .01), with similar rates of massive transfusion (9% vs 7%; P = 1.0). Converted patients also had a higher incidence of postoperative acuity (47% vs 4%; P < .0001), including 5 intensive care unit admissions for airway management after large-volume resuscitation. After adjusting for multiple confounders, the only independent predictors of conversion among hysterectomy patients were longer surgical duration (adjusted odds ratio 1.54, 95% CI, 1.01-2.42) and a history of ≥3 prior CDs (adjusted odds ratio, 6.45; 95% CI, 1.12-45.03).
CONCLUSIONS: NA was applied to and successfully used in the majority of patients with suspected MAP. Our findings support selective conversion to GA during hysterectomy in these patients, focusing on those with the highest levels of surgical complexity.

Entities:  

Mesh:

Year:  2018        PMID: 29481427     DOI: 10.1213/ANE.0000000000003314

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

Review 1.  General anaesthesia in obstetrics.

Authors:  C Delgado; L Ring; M C Mushambi
Journal:  BJA Educ       Date:  2020-04-21

Review 2.  Management of patients with suspected placenta accreta spectrum.

Authors:  S C Reale; M K Farber
Journal:  BJA Educ       Date:  2021-12-21

3.  Placenta accreta spectrum anaesthetic management with neuraxial technique can be facilitated by multidisciplinary groups.

Authors:  Leidy Johanna Lopez-Erazo; Beatriz Sánchez; Luisa Femanda Blanco; Albaro Jose Nieto-Calvache
Journal:  Indian J Anaesth       Date:  2021-02-10

4.  Peripartum Ηysterectomy: A Four-Year Obstetric and Anesthetic Experience in a Tertiary Referral Hospital in Greece.

Authors:  Michael Sindos; Konstantinos Kalmantis; Konstantinos Samartzis; Michail Diakosavvas; Andreas Kalampalikis; Konstantina Kalopita; Emmanouil Stamatakis; Dimitrios Valsamidis; George Daskalakis
Journal:  Cureus       Date:  2022-05-17

Review 5.  Coagulation abnormalities and bleeding in pregnancy: an anesthesiologist's perspective.

Authors:  Hea-Jo Yoon
Journal:  Anesth Pain Med (Seoul)       Date:  2019-10-31

6.  Anesthesia for Cesarean Section in Parturients with Abnormal Placentation: A Retrospective Study.

Authors:  Orhan Binici; Evren Büyükfırat
Journal:  Cureus       Date:  2019-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.